Translational Tumor Immunology

The Translational Tumor Immunology program is focused on investigation of the mechanisms regulating immune responses in cancer and their potential therapeutic manipulation.  The translational component, namely understanding the mechanisms operational in cancer patients, is a special emphasis of the program.  Members of the program are largely concentrated over three large areas: myeloid cells (dendritic cells, macrophages, neutrophils and myeloid-derived suppressor cells), regulatory T cells and B cells, and infectious diseases.


Members:

Dmitry Gabrilovich, M.D., Ph.D., Program Leader
Mohamed Abdel-Mohsen, Ph.D.
Andrew Caton, Ph.D.
Farokh Dotiwala, M.B.B.S., Ph.D.
Andrew Hu, Ph.D.
Luis Montaner, D.V.M., D.Phil.
Kar Muthumani, M.Sc., Ph.D.
Erica Stone, Ph.D.
David Weiner, Ph.D.